Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer

BACKGROUND: Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to specific glycolipid antigens such as α-galactosylceramide (αGalCer) presented by CD1d-expressing antigen-presenting cells (APCs), thus orchestrating other immune cells to fight tumors. Because of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Toyoda, Takahide, Kamata, Toshiko, Tanaka, Kazuhisa, Ihara, Fumie, Takami, Mariko, Suzuki, Hidemi, Nakajima, Takahiro, Ikeuchi, Takayuki, Kawasaki, Yohei, Hanaoka, Hideki, Nakayama, Toshinori, Yoshino, Ichiro, Motohashi, Shinichiro
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Immune Cell Therapies and Immune Cell Engineering
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7078938/
https://ncbi.nlm.nih.gov/pubmed/32188702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000316
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы